-
Tytuł:
-
Estimating Quality of Life Decrements in Oncology Using Time to Death.
-
Autorzy:
-
Versteegh M; Institute for Medical Technology Assessment, Erasmus University Rotterdam, Rotterdam, The Netherlands. Electronic address: .
van der Helm I; Erasmus School of Health Policy & Management, Erasmus University Rotterdam, Rotterdam, The Netherlands.
Mokri H; Erasmus School of Health Policy & Management, Erasmus University Rotterdam, Rotterdam, The Netherlands.
Oerlemans S; Department of Research and Development, Netherlands Comprehensive Cancer Organisation, Utrecht, The Netherlands.
Blommestein H; Erasmus School of Health Policy & Management, Erasmus University Rotterdam, Rotterdam, The Netherlands.
van Baal P; Erasmus School of Health Policy & Management, Erasmus University Rotterdam, Rotterdam, The Netherlands.
-
Źródło:
-
Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research [Value Health] 2022 Oct; Vol. 25 (10), pp. 1673-1677. Date of Electronic Publication: 2022 Jul 06.
-
Typ publikacji:
-
Journal Article
-
Język:
-
English
-
Imprint Name(s):
-
Publication: Jan./Feb. 2011- : New York : Elsevier
Original Publication: Malden, MA : Blackwell Science, c1998-
-
MeSH Terms:
-
Medical Oncology*
Quality of Life*
Cost-Benefit Analysis ; Humans ; Netherlands/epidemiology ; Quality-Adjusted Life Years ; Surveys and Questionnaires
-
Contributed Indexing:
-
Keywords: time to death
-
Entry Date(s):
-
Date Created: 20220708 Date Completed: 20221018 Latest Revision: 20221116
-
Update Code:
-
20240105
-
DOI:
-
10.1016/j.jval.2022.06.002
-
PMID:
-
35803844
-
Objectives: The estimation of lifetime quality-adjusted life-years (QALYs) requires the extrapolation of both length and quality of life (QoL). The extrapolation of QoL has received little attention in the literature. Here we explore the predictive value of "time to death" (TTD) for extrapolating QoL in oncology.
Methods: We used QoL and survival data from the Patient Reported Outcomes Following Initial Treatment and Long-Term Evaluation of Survivorship registry, which is linked to The Netherlands Cancer Registry. QoL was assessed with EQ-5D and SF-6D. We tested the relationship between TTD and QoL using linear, 2-part, and beta regression models. Incremental QALYs were compared using the TTD approach and an annual age-related disutility approach using artificial survival data with varying mortality rates.
Results: A total of 6 samples with >100 patients each were used for the analysis. A declining pattern in QoL was observed when patients were closer to death, confirming the predictive value of TTD for QoL. The declining pattern in QoL was most pronounced when QoL was measured with SF-6D. Proximity to death had a larger impact on QoL than age. Incremental QALYs were higher using the TTD approach than annual age-related disutility, ranging from +0.139 to +0.00003 depending on mortality rates.
Conclusions: TTD is a predictor variable for QoL. Using TTD allows cost-effectiveness models that lack QoL data to extrapolate morbidity using overall survival estimates. The TTD approach generates more incremental QALYs than an annual age-related disutility, most notably for longer survival periods.
(Copyright © 2022. Published by Elsevier Inc.)
